Erin R Rieke1, Juan Amaral, S Patricia Becerra, Robert J Lutz. 1. Laboratory of Bioengineering and Physical Sciences, National Institute of Biomedical Imaging and Bioengineering, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892-5766, USA.
Abstract
PURPOSE: An effective treatment modality for posterior eye diseases would provide prolonged delivery of therapeutic agents, including macromolecules, to eye tissues using a safe and minimally invasive method. The goal of this study was to assess the ability of a thermosetting gel to deliver a fluorescently labeled protein, Alexa 647 ovalbumin, to the choroid and retina of rats following a single subconjunctival injection of the gel. Additional experiments were performed to compare in vitro to in vivo ovalbumin release rates from the gel. METHODS: The ovalbumin content of the eye tissues was monitored by spectrophotometric assays of tissue extracts of Alexa 647 ovalbumin from dissected sclera, choroid, and retina at time points ranging from 2 h to 14 days. At the same time points, fluorescence microscopy images of tissue samples were also obtained. Measurement of intact ovalbumin was verified by LDS-PAGE analysis of the tissue extract solutions. In vitro release of Alexa 488 ovalbumin into 37 degrees C PBS solutions from ovalbumin-loaded gel pellets was also monitored over time by spectrophotometric assay. In vivo ovalbumin release rates were determined by measurement of residual ovalbumin extracted from gel pellets removed from rat eyes at various time intervals. RESULTS: Our results indicate that ovalbumin concentrations can be maintained at measurable levels in the sclera, choroid, and retina of rats for up to 14 days using the thermosetting gel delivery system. The concentration of ovalbumin exhibited a gradient that decreased from sclera to choroid and to retina. The in vitro release rate profiles were similar to the in vivo release profiles. CONCLUSIONS: Our findings suggest that the thermosetting gel system may be a feasible method for safe and convenient sustained delivery of proteins to choroidal and retinal tissue in the posterior segments of the eye.
PURPOSE: An effective treatment modality for posterior eye diseases would provide prolonged delivery of therapeutic agents, including macromolecules, to eye tissues using a safe and minimally invasive method. The goal of this study was to assess the ability of a thermosetting gel to deliver a fluorescently labeled protein, Alexa 647 ovalbumin, to the choroid and retina of rats following a single subconjunctival injection of the gel. Additional experiments were performed to compare in vitro to in vivo ovalbumin release rates from the gel. METHODS: The ovalbumin content of the eye tissues was monitored by spectrophotometric assays of tissue extracts of Alexa 647 ovalbumin from dissected sclera, choroid, and retina at time points ranging from 2 h to 14 days. At the same time points, fluorescence microscopy images of tissue samples were also obtained. Measurement of intact ovalbumin was verified by LDS-PAGE analysis of the tissue extract solutions. In vitro release of Alexa 488 ovalbumin into 37 degrees C PBS solutions from ovalbumin-loaded gel pellets was also monitored over time by spectrophotometric assay. In vivo ovalbumin release rates were determined by measurement of residual ovalbumin extracted from gel pellets removed from rat eyes at various time intervals. RESULTS: Our results indicate that ovalbumin concentrations can be maintained at measurable levels in the sclera, choroid, and retina of rats for up to 14 days using the thermosetting gel delivery system. The concentration of ovalbumin exhibited a gradient that decreased from sclera to choroid and to retina. The in vitro release rate profiles were similar to the in vivo release profiles. CONCLUSIONS: Our findings suggest that the thermosetting gel system may be a feasible method for safe and convenient sustained delivery of proteins to choroidal and retinal tissue in the posterior segments of the eye.
Authors: Hong Li; Veronique V Tran; Yueyue Hu; W Mark Saltzman; Colin J Barnstable; Joyce Tombran-Tink Journal: Exp Eye Res Date: 2006-07-05 Impact factor: 3.467
Authors: G M Zentner; R Rathi; C Shih; J C McRea; M H Seo; H Oh; B G Rhee; J Mestecky; Z Moldoveanu; M Morgan; S Weitman Journal: J Control Release Date: 2001-05-14 Impact factor: 9.776
Authors: David S Friedman; Benita J O'Colmain; Beatriz Muñoz; Sandra C Tomany; Cathy McCarty; Paulus T V M de Jong; Barbara Nemesure; Paul Mitchell; John Kempen Journal: Arch Ophthalmol Date: 2004-04
Authors: Yingli Fu; M Lourdes Ponce; Michelle Thill; Peng Yuan; Nam Sun Wang; Karl G Csaky Journal: Invest Ophthalmol Vis Sci Date: 2007-11 Impact factor: 4.799
Authors: Pui Shan Chan; Jia Wen Xian; Qingqing Li; Chun Wai Chan; Sharon S Y Leung; Kenneth K W To Journal: AAPS J Date: 2019-04-24 Impact factor: 4.009
Authors: Uri Soiberman; Siva P Kambhampati; Tony Wu; Manoj K Mishra; Yumin Oh; Rishi Sharma; Jiangxia Wang; Abdul Elah Al Towerki; Samuel Yiu; Walter J Stark; Rangaramanujam M Kannan Journal: Biomaterials Date: 2017-02-16 Impact factor: 12.479
Authors: Ivan T Rebustini; Alexandra Bernardo-Colón; Alejandra Isasi Nalvarte; S Patricia Becerra Journal: Int J Mol Sci Date: 2021-05-19 Impact factor: 5.923
Authors: Eliana B Souto; João Dias-Ferreira; Ana López-Machado; Miren Ettcheto; Amanda Cano; Antonio Camins Espuny; Marta Espina; Maria Luisa Garcia; Elena Sánchez-López Journal: Pharmaceutics Date: 2019-09-06 Impact factor: 6.321
Authors: Mariano Mora-Pereira; Eva M Abarca; Sue Duran; William Ravis; Richard J McMullen; Britta M Fischer; Yann-Huei Phillip Lee; Anne A Wooldridge Journal: BMC Vet Res Date: 2020-04-16 Impact factor: 2.741